HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control.

Abstract
NK cell activation has been shown to be metabolically regulated in vitro; however, the role of metabolism during in vivo NK cell responses to infection is unknown. We examined the role of glycolysis in NK cell function during murine cytomegalovirus (MCMV) infection and the ability of IL-15 to prime NK cells during CMV infection. The glucose metabolism inhibitor 2-deoxy-ᴅ-glucose (2DG) impaired both mouse and human NK cell cytotoxicity following priming in vitro. Similarly, MCMV-infected mice treated with 2DG had impaired clearance of NK-specific targets in vivo, which was associated with higher viral burden and susceptibility to infection on the C57BL/6 background. IL-15 priming is known to alter NK cell metabolism and metabolic requirements for activation. Treatment with the IL-15 superagonist ALT-803 rescued mice from otherwise lethal infection in an NK-dependent manner. Consistent with this, treatment of a patient with ALT-803 for recurrent CMV reactivation after hematopoietic cell transplant was associated with clearance of viremia. These studies demonstrate that NK cell-mediated control of viral infection requires glucose metabolism and that IL-15 treatment in vivo can reduce this requirement and may be effective as an antiviral therapy.
AuthorsAnnelise Y Mah, Armin Rashidi, Molly P Keppel, Nermina Saucier, Emily K Moore, Joshua B Alinger, Sandeep K Tripathy, Sandeep K Agarwal, Emily K Jeng, Hing C Wong, Jeffrey S Miller, Todd A Fehniger, Emily M Mace, Anthony R French, Megan A Cooper
JournalJCI insight (JCI Insight) Vol. 2 Issue 23 (12 07 2017) ISSN: 2379-3708 [Electronic] United States
PMID29212951 (Publication Type: Case Reports, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • ALT-803
  • Actins
  • Antiviral Agents
  • Blood Glucose
  • Interleukin-15
  • Proteins
  • Recombinant Fusion Proteins
  • Interferon-gamma
  • Deoxyglucose
  • Granzymes
  • Gzmb protein, mouse
Topics
  • Actins (metabolism)
  • Animals
  • Antiviral Agents (pharmacology, therapeutic use)
  • Blood Glucose (metabolism)
  • Cell Proliferation (drug effects)
  • Cells, Cultured
  • Cytomegalovirus (physiology)
  • Cytomegalovirus Infections (drug therapy, immunology, virology)
  • Cytotoxicity, Immunologic (drug effects, immunology)
  • Deoxyglucose (pharmacology)
  • Female
  • Glycolysis (drug effects, immunology)
  • Granzymes (metabolism)
  • Herpesviridae Infections (drug therapy, immunology, prevention & control, virology)
  • Humans
  • Interferon-gamma (biosynthesis)
  • Interleukin-15 (agonists, immunology)
  • Killer Cells, Natural (drug effects, immunology)
  • Male
  • Mice, Inbred C57BL
  • Muromegalovirus (isolation & purification)
  • Proteins (pharmacology, therapeutic use)
  • Recombinant Fusion Proteins
  • Viral Load (drug effects)
  • Virus Activation
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: